CTOs on the Move

Healthlogix

www.hlxusa.com

 
Healthlogix is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.hlxusa.com
  • 99 Cherry Hill Rd
    Parsippany, NJ USA 07054
  • Phone: 973.401.1600

Executives

Name Title Contact Details

Similar Companies

Capstone Development Services,

Capstone Development Services is a shared services development company focused on complex generic pharmaceuticals and medical devices. Capstone leads development, manages regulatory services, and achieves timely approval of healthcare products through ...

Caron Products and Services

Caron Products is a provider of incubators & chambers for cell growth and product environmental testing in biological research, scale-up culture, and drug and biological QA/QC testing. Caron`s products are integral to workflows ranging from cell & gene therapy to medical device manufacturing. Caron`s expanding resources, with manufacturing facilities in both the USA and Europe, and a worldwide network of sales and service personnel aligns with the needs of the global biomedical industry.

Lighthouse Behavioral Health Solutions

Substance Use Disorder and Mental Health Residential, Outpatient and Recovery Housing. Accepts all Medicaid. Holistic 360’ approach.

Roche

606018 F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.